A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Qi, Qi
Liu, Yang
Li, Rentao
Liu, Yayue
Zhang, Xihao
Lu, Wei
Li, Huikai
机构：
[1] Tianjin Canc Hosp, Airport Hosp, Dept Hepatobiliary & Pancreat Oncol, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Liver Canc Ctr, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16154
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
    Parikh, Neehar D.
    Singal, Amit G.
    Hutton, David W.
    CANCER, 2017, 123 (19) : 3725 - 3731
  • [2] Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
    Li, B-K.
    Yuan, Y.
    Qiao, L.
    He, W.
    Wang, G.
    Chen, H.
    Zhang, B.
    Fuxi, H.
    Qiu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S596 - S596
  • [3] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [4] Regorafenib as second-line therapy in hepatocellular carcinoma
    Austin G. Duffy
    Tim F. Greten
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 141 - 142
  • [5] Hepatocellular Carcinoma: Successes with Regorafenib in Second-line Therapy
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (05):
  • [6] Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study
    Tsang, Erica S.
    Davies, Janine Marie
    Loree, Jonathan M.
    Lim, Howard John
    Renouf, Daniel John
    Gill, Sharlene
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
    Trojan, Joerg
    Waidmann, Oliver
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 31 - 36
  • [9] Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study
    Lu, J.
    Zhu, H.
    Guo, J.
    Teng, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S671 - S671
  • [10] A phase Ib study of anlotinib plus TQB2450 as a second-line investigational therapy in advanced hepatocellular carcinoma (aHCC).
    Zhang, Wen
    Sun, Yongkun
    Zeng, Huiying
    Zhu, Zheng
    Liang, Meng
    Han, Yue
    Yan, Dong
    Chen, Bo
    Huang, Zhen
    Bi, Xinyu
    Zhao, Hong
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16184 - E16184
12345